(0.33%) 5 116.92 points
(0.32%) 38 364 points
(0.38%) 15 988 points
(-0.98%) $83.03
(5.51%) $2.03
(0.32%) $2 354.60
(0.45%) $27.66
(4.12%) $960.10
(-0.26%) $0.932
(-0.46%) $10.97
(-0.57%) $0.796
(1.66%) $93.40
Live Chart Being Loaded With Signals
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called cytokine storm'...
Stats | |
---|---|
本日の出来高 | 2.06M |
平均出来高 | 341 846 |
時価総額 | 23 816.00 |
EPS | $0 ( 2024-03-28 ) |
次の収益日 | ( $0 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.000392 |
ATR14 | $0.00100 (1 000.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-10-18 | Chappell Dale | Sell | 276 210 | Common Stock, $0.001 par value |
2023-10-18 | Chappell Dale | Sell | 75 887 | Common Stock, $0.001 par value |
2023-10-18 | Chappell Dale | Sell | 34 253 | Common Stock, $0.001 par value |
2022-07-27 | Buxton Cheryl | Buy | 78 362 | Stock Option (Right to Buy) |
2022-07-27 | Hohneker John | Buy | 63 195 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
37.51 |
Last 98 transactions |
Buy: 5 830 886 | Sell: 2 957 610 |
ボリューム 相関
Humanigen, Inc. 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Humanigen, Inc. 相関 - 通貨/商品
Humanigen, Inc. 財務諸表
Annual | 2022 |
収益: | $2.51M |
総利益: | $2.51M (100.00 %) |
EPS: | $-1.180 |
FY | 2022 |
収益: | $2.51M |
総利益: | $2.51M (100.00 %) |
EPS: | $-1.180 |
FY | 2021 |
収益: | $3.60M |
総利益: | $0.00 (0.00 %) |
EPS: | $-3.98 |
FY | 2020 |
収益: | $312 000 |
総利益: | $0.00 (0.00 %) |
EPS: | $-2.42 |
Financial Reports:
No articles found.
Humanigen, Inc.
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1. Ifabotuzumab has been evaluated in a Phase 1 study of glioblastoma multiforme that showed tumor specific targeting of all known tumor sites with no normal tissue uptake. HGEN005 is being explored as a treatment for a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。